Secondary efficacy endpoints (ITT population): estimated between-group differences
| Baseline mean (SE) | Week 26 mean/overall mean (SE) | Estimated change (SE) | Estimated between-group difference | p Value | |
| WOMAC A (pain) change from baseline at 26 weeks* | |||||
| Hylan G-F 20 | 2.30 (0.04) | 1.51 (0.074) | −0.76 (0.07) | −0.18 (0.097) | 0.064 |
| Placebo | 2.25 (0.04) | 1.69 (0.073) | −0.58 (0.07) | ||
| WOMAC C (function) change from baseline over 26 weeks† | |||||
| Hylan G-F 20 | 2.29 (0.04) | 1.62 (0.061) | −0.66 (0.061) | −0.03 (0.077) | 0.679 |
| Placebo | 2.28 (0.04) | 1.66 (0.059) | −0.63 (0.059) | ||
| WOMAC C (function) change from baseline at 26 weeks† | |||||
| Hylan G-F 20 | 2.29 (0.04) | 1.69 (0.076) | −0.59 (0.076) | −0.11 (0.100) | 0.266 |
| Placebo | 2.28 (0.04) | 1.80 (0.074) | −0.48 (0.074) |
*Week 26 mean in column 3; †overall mean in column 3. ITT, intent-to-treat; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.